QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10(yyy)

         LOGO [g567179.jpg]

FORM OF SECURED PROMISSORY NOTE

[$ AMOUNT]   [DATE]

        FOR VALUE RECEIVED, ALLIANCE PHARMACEUTICAL CORP., a New York
corporation (the "Company"), hereby promises to pay to the order of [HOLDER]
(the "Holder"), at [ADDRESS], the principal amount of                        
($            ) in lawful money of the United States of America, on the terms
set forth in Section 1 hereof. This Note is secured by a first priority security
interest in certain assets of the Company (the "Collateral") pursuant to the
Security Agreement, dated as of July 23, 2002 (the "Security Agreement"),
between the Company and the Holder and the Patent and Trademark Security
Agreement, dated as of July 23, 2002 (the "Patent and Trademark Security
Agreement") between the Company and the Holder.

        1.    Payments of Interest and Principal.    Subject to the provisions
of Section 2 hereunder, payments of principal plus interest on the unpaid
principal balance of this Promissory Note (this "Note") outstanding from time to
time shall be payable in accordance with the following:

        (a)    Interest.    During the period commencing on the date hereof and
terminating on [45 days from the date hereof], no interest shall accrue. If the
Maturity Date hereunder is extended pursuant to Section 1(b) below, interest
shall accrue commencing on [46 days from the date hereof] at a rate equal to
$                        per day, or if such rate exceeds the maximum rate
permitted to be charged under applicable law, the maximum rate allowed
thereunder.

        (b)    Principal.    The principal balance outstanding on this Note
shall be due and payable to the Holder at the earlier of (i) [45 days from the
date hereof], or (ii) the date on which the Company completes and receives the
proceeds from a financing with aggregate gross proceeds of at least
$            (the "Maturity Date"). Notwithstanding the above, the Maturity Date
may be extended 90 days from the date hereof by written notice from the Company
to the Holder, in which case, the principal balance outstanding on this Note and
the accrued interest thereon shall be due and payable on such 90th day,
provided, however, that the Maturity Date may not be extended beyond the date
any financing is completed and the Company receives the proceeds therefrom as
contemplated in the preceding sentence. Contemporaneously with the repayment of
this Note, the Holder shall surrender this Note, duly endorsed, at the office of
the Company.

        (c)    Payments.    All payments of principal, interest, fees and other
amounts due hereunder shall be made by the Company in lawful money of the United
States of America by wire transfer or by any other method approved in advance by
the Holder to the account of the Holder at the address of the Holder set forth
in Section 4 hereof or at such other place designated by the Holder in writing
to the Company.

        (d)    Acceleration of the Maturity Date.    Notwithstanding any other
provision in this Note to the contrary, this Note shall become due and payable
together with all accrued interest due on the outstanding principal amount
hereunder, without notice or any other action by Holder, in the event that
(i) the Company fails to pay the principal of or interest on this Note as and
when due; (ii) the Company shall default in the performance of or otherwise
breach any of its representations and warranties or other obligations set forth
in the Secured Note Purchase Agreement, dated as of July 23, 2002, between the
Company and the Holder for a period of 30 consecutive days without cure by the
Company; (iii) the Holder shall have the right to enforce it's remedies under
Section 8 of the Security Agreement or Section 7 of the Patent and Trademark
Security Agreement; (iv) the

1

--------------------------------------------------------------------------------

Holder shall not have a first priority security interest in the Collateral once
all necessary filings have been made under the Security Agreement and the Patent
and Trademark Security Agreement; (v) the Company shall file a petition under
bankruptcy, insolvency or debtor's relief law or make an assignment for the
benefit of its creditors; or (vi) a court of competent jurisdiction enters an
order or decree under any federal or state bankruptcy law that (X) is for relief
against the Company in an involuntary case brought with respect to the Company
in such court, (Y) appoints a custodian, receiver or other similar official for
all or substantially all the Company's property or (Z) orders the liquidation of
the Company, and the order or decree remains unstayed and in effect for sixty
(60) days. In the event that the payment of principal and interest due hereunder
is accelerated pursuant to this Section 1(d), interest shall accrue at a rate
equal to $                        per day as of the date of such acceleration
until such date as the Holder is paid in full under this Note.

        2.    Prepayment.    The principal balance of this Note, along with all
accrued interest, if any, may be paid in full at the election of the Company at
any time upon no less than two (2) days prior written notice to the Holder.

        3.    Governing Law.    This Note shall be governed by and construed in
accordance with the domestic substantive laws of the State of New York, without
giving effect to any choice or conflict of law provision or rule that would
cause the application of the laws of any other jurisdiction.

        4.    Notices.    All notices and other communications given to any
party hereto pursuant to this Agreement shall be in writing and shall be
delivered, or mailed first class postage prepaid, registered or certified mail,
addressed as follows:

(a)If to the Company, to:

Alliance Pharmaceutical Corp.
3040 Science Park Road
San Diego, California 92121
Fax number: (858) 410-5306
Attention: President

with a copy to:

Stroock & Stroock & Lavan LLP
180 Maiden Lane
New York, NY 10038
Fax number: (212) 806-6006
Attention: Melvin Epstein, Esq.

(b)If to the Holder, to:

[HOLDER]
[ADDRESS]
Fax number:                                                   
Attention:                                                   

Each such notice or other communication shall for all purposes be treated as
being effective or having been given when delivered, if delivered personally, by
e-mail or facsimile with confirmation of receipt or by overnight courier or, if
sent by mail, at the earlier of its actual receipt or three (3) days after the
same has been deposited in a regularly maintained receptacle for the deposit of
United States mail, addressed and postage prepaid as aforesaid.

        5.    Company's Waivers.    The Company, to the extent permitted by law,
waives and agrees not to assert or take advantage of any of the following:
(a) any defense based upon an election of remedies by

2

--------------------------------------------------------------------------------

the Holder which may destroy or otherwise impair any subrogation or other rights
of the Company or any guarantor or endorser of this Note; (b) any duty on the
part of the Holder to disclose any facts or other data the Holder may now or
hereafter know; (c) acceptance or notice of acceptance of this Note by the
Company; (d) presentment and/or demand for payment of this Note or any
indebtedness or obligations hereby promised; and (e) protest and notice of
dishonor with respect to this Note or any indebtedness or performance of
obligations arising hereunder.

        6.    Amendment; Waiver.    All amendments or waivers of any of the
terms hereof (including, without limitation, any waiver of acceleration of the
Maturity Date) and any payment of this Note with any consideration other than
cash, shall be made or effected only with the written consent of the Holder.

        7.    Replacement of Note.    Upon receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction, or mutilation of
this Note by the Holder, the Company shall issue a replacement instrument, at
the Company's expense, representing such Note in lieu of such lost, stolen,
destroyed, or mutilated instrument, provided that the Holder agrees to indemnify
the Company for any losses incurred by the Company with respect to such lost
instrument (other than the cost of issuing the new instrument).

        8.    Warrant.    This Note is being issued together with a warrant to
purchase shares of common stock of the Company.

        9.    Headings.    The headings of the sections of this Note are
inserted for convenience only and do not constitute a part of this Note.

        IN WITNESS WHEREOF, the Company has caused this Note to be signed and to
be dated the day and year first above written.

 
 
ALLIANCE PHARMACEUTICAL CORP.
 
 
By:
 
         

--------------------------------------------------------------------------------

        Name: Theodore D. Roth
Title: President and Chief Operating Officer

3

--------------------------------------------------------------------------------

QuickLinks

FORM OF SECURED PROMISSORY NOTE